Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis

European Respiratory Journal

Volumn 55, Issue 5, 2020, Pages

  Guan, Wei Jie ^a   Liang, Wen Hua ^a   Zhao, Yi ^a   Liang, Heng Rui ^a   Chen, Zi Sheng ^a   Li, Yi Min ^a   Liu, Xiao Qing ^a   Chen, Ru Chong ^a   Tang, Chun Li ^a   Wang, Tao ^a   Ou, Chun Quan ^b   Li, Li ^b   Chen, Ping Yan ^b   Sang, Ling ^a   Wang, Wei ^a   Li, Jian Fu ^a   Li, Cai Chen ^a   Ou, Li Min ^a   Cheng, Bo ^a   Xiong, Shan ^a   Ni, Zheng Yi ^c   Xiang, Jie ^c   Hu, Yu ^d   Liu, Lei ^e   Shan, Hong ^f   Lei, Chun Liang ^a   Peng, Yi Xiang ^g   Wei, Li ^h   Liu, Yong ⁱ   Hu, Ya Hua ^j   Peng, Peng ^k   Wang, Jian Ming ^l   Liu, Ji Yang ^m   Chen, Zhong ⁿ   Li, Gang ^o   Zheng, Zhi Jian ^p   Qiu, Shao Qin ^q   Luo, Jie ^r   Ye, Chang Jiang ^s   Zhu, Shao Yong ^t   Cheng, Lin Ling ^a   Ye, Feng ^a   Li, Shi Yue ^a   Zheng, Jin Ping ^a   Zhang, Nuo Fu ^a   Zhong, Nan Shan ^a   He, Jian Xing ^a   more..

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Wuhan JinYinTan Hospital   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^f THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^g CENTRAL HOSPITAL OF WUHAN   (China)

^h WUHAN NO 1 HOSPITAL   (China)

ⁱ Chengdu Public Health Clinical Center   (China)

^j HUBEI POLYTECHNIC UNIVERSITY   (China)

^k Wuhan Center Hospital   (China)

^l WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^m First Hospital of Changsha   (China)

ⁿ The Third People Hospital of Hainan Province   (China)

^o Huanggang Central Hospital   (China)

^p THE FIRST PEOPLE S HOSPITAL OF WENLING   (China)

^q Third People's Hospital of Yichang   (China)

^r HUBEI UNIVERSITY OF MEDICINE   (China)

^s Xiantao First People's Hospital   (China)

^t RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

more..

Author keywords

Cardiovascular disease; Chronic obstructive pulmonary disease; Diabetes; Hypertension; Malignancy; Mortality

Indexed keywords

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; CARDIOVASCULAR DISEASE; CASE STUDY; CHINA; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; CORONAVIRUS DISEASE 2019; DIABETES MELLITUS; EPIDEMIC; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY RATE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT; SYMPTOMATOLOGY; BETACORONAVIRUS; CORONAVIRUS INFECTION; MIDDLE AGED; PANDEMIC; PROGNOSIS; RISK FACTOR; VIRUS PNEUMONIA;

ADULT; BETACORONAVIRUS; CHINA; COMORBIDITY; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; PROGNOSIS; RISK FACTORS;

EID: 85083215090     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00547-2020     Document Type: Article

References (36)

1. th, 2020)
2. th, 2020)
3. Huang C, Wang Y, Li X, et al. Clinical features of patients with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; doi: 10.1016/S0140-6736(20)30183-5
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020. doi: 10.1016/S0140-6736(20)30211-7
5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585
6. Kui L, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 Feb 7. doi: 10.1097/CM9.0000000000000744
7. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case studies. BMJ. 2020; 368:m606
8. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; doi: 10.1016/S0140-6736(20)30154-9
9. Zhang S, Li H, Huang S, et al. High-resolution CT features of 17 cases of Corona Virus Disease 2019 in Sichuan province, China. Eur Respir J. 2020; DOI: 10.1183/13993003.00334-2020
10. Wang L, Gao YH, Iou L, Zhang GJ. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J. 2020; DOI: 10.1183/13993003.00398-2020
11. Yao Y, Tian Y, Zhou J, et al. Epidemiological characteristics of 2019-ncoV infections in Shaanxi, China by February 8, 2020. Eur Respir J. 2020; 2000310. DOI: 10.1183/13993003.00310-2020
12. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. doi: 10.1056/NEJMoa2002032
13. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013; 368:2277-85
14. Placzek HED, Madoff LC. Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. Am J Public Health. 2014;104:e118-e125
15. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications in different high-risk groups. J Med Economics. 2013;16:264-77
16. Shiley KT, Nadolski G, Mickus T, et al. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol. 2010; 31: 676-682
17. Martinez A, Soldevila N, Romeo-Tamarit A, et al. Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype. Plos One. 2019;14:e0210353
18. Gutiérrez-González E, Cantero-Escribano JM, Redondo-Bravo L, et al. Effect of vaccination, comorbidities and age on mortality and severe disease associated with influenza during the season 2016-2017 in a Spanish tertiary hospital. J Infect Public Health. 2019;12:486-491
19. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-2809
20. Alqahtani FY, Aleanizy FS, Ali Hadi Mohammed R, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect. 2018;5:1-5
21. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV). Int J Infect Dis. 2016;49:129-133
22. Rahman A, Sarkar A. Risk Factors for Fatal Middle East Respiratory Syndrome Coronavirus Infections in Saudi Arabia: Analysis of the WHO Line List, 2013-2018. Am J Public Health. 2019;305186
23. Alanazi KH, Abedi GR, Midgley CM, et al. Diabetes Mellitus, Hypertension, and Death among 32 Patients with MERS-CoV Infection, Saudi Arabia. Emerging Infect Dis. 2020;26:166-168
24. Yang YM, Hsu CY, Lai CC, et al. Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. Sci Rep. 2017;7:11307
25. Garbati MA, Fagbo SF, Fang VJ, et al. A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. Plos One. 2016;11:e0165978
26. Rivers CM, Majumder MS, Lofgren ET. Risks of Death and Severe Disease in Patients With Middle East Respiratory Syndrome Coronavirus, 2012-2015. Am J Epidemiol. 2016;184:460-464
27. Kulscar KA, Coleman CM, Beck S, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;20:e131774
28. Matsuyama R, Nishiura H, Kutsuna S, et al. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health. 2016;16:1203
29. th, 2020)
30. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America. Am J Respir Crit Care Med. 2019; 200:e45-e67
31. Li HY, Guo Q, Song WD, et al. Mortality among severe community-acquired pneumonia patients depends on combinations of 2007IDSA/ATS minor criteria. Int J Infect Dis. 2015;38:141-5
32. Gearhart AM, Furmanek S, English C, Ramirez J, Cavallazzi R. Predicting the need for ICU admission in community-acquired pneumonia. Respir Med. 2019;155:61-65
33. Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6:421-430
34. Moni MA, Lionel P. Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies. BMC Bioinformatics 2014, 15:333
35. Naqvi AA, Shah A, Ahmad R, Ahmad N. Developing an Integrated Treatment Pathway for a Post-Coronary Artery Bypass Grating (CABG) Geriatric Patient with Comorbid Hypertension and Type 1 Diabetes Mellitus for Treating Acute Hypoglycemia and Electrolyte Imbalance. J Pharm Bioallied Sci. 2017;9:216-220
36. Murphy TE, McAvay GJ, Allore HG, et al. Contributions of COPD, asthma, and ten comorbid conditions to health care utilization and patient-centered outcomes among US adults with obstructive airway disease. Int J Chron Obstruct Pulmon Dis. 2017;12:2515-2522